GYRE
Price
$6.73
Change
-$0.01 (-0.15%)
Updated
Sep 11 closing price
Capitalization
713.61M
67 days until earnings call
Intraday BUY SELL Signals
NKTX
Price
$2.91
Change
+$0.10 (+3.56%)
Updated
Sep 11 closing price
Capitalization
208.43M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

GYRE vs NKTX

GYRE vs NKTX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
GYRE vs. NKTX commentary
Sep 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a Buy and NKTX is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($714M) has a higher market cap than NKTX($208M). NKTX YTD gains are higher at: 57.297 vs. GYRE (-4.674). GYRE has higher annual earnings (EBITDA): -12.13M vs. NKTX (-122.62M). NKTX has more cash in the bank: 183M vs. GYRE (74.8M). GYRE has less debt than NKTX: GYRE (3.42M) vs NKTX (73.5M). GYRE has higher revenues than NKTX: GYRE (110M) vs NKTX (0).
GYRENKTXGYRE / NKTX
Capitalization714M208M343%
EBITDA-12.13M-122.62M10%
Gain YTD-4.67457.297-8%
P/E Ratio390.00N/A-
Revenue110M0-
Total Cash74.8M183M41%
Total Debt3.42M73.5M5%
FUNDAMENTALS RATINGS
GYRE vs NKTX: Fundamental Ratings
GYRE
NKTX
OUTLOOK RATING
1..100
8638
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
10
Undervalued
PROFIT vs RISK RATING
1..100
91100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
5539
P/E GROWTH RATING
1..100
6100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NKTX's Valuation (10) in the null industry is significantly better than the same rating for GYRE (99). This means that NKTX’s stock grew significantly faster than GYRE’s over the last 12 months.

GYRE's Profit vs Risk Rating (91) in the null industry is in the same range as NKTX (100). This means that GYRE’s stock grew similarly to NKTX’s over the last 12 months.

GYRE's SMR Rating (95) in the null industry is in the same range as NKTX (97). This means that GYRE’s stock grew similarly to NKTX’s over the last 12 months.

NKTX's Price Growth Rating (39) in the null industry is in the same range as GYRE (55). This means that NKTX’s stock grew similarly to GYRE’s over the last 12 months.

GYRE's P/E Growth Rating (6) in the null industry is significantly better than the same rating for NKTX (100). This means that GYRE’s stock grew significantly faster than NKTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GYRENKTX
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 4 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
74%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
COMPARISON
Comparison
Sep 13, 2026
Stock price -- (GYRE: $6.73 vs. NKTX: $2.91)
Brand notoriety: GYRE and NKTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 102% vs. NKTX: 74%
Market capitalization -- GYRE: $713.61M vs. NKTX: $208.43M
GYRE [@Biotechnology] is valued at $713.61M. NKTX’s [@Biotechnology] market capitalization is $208.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 1 FA rating(s) are green while NKTX’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 1 green, 4 red.
  • NKTX’s FA Score: 1 green, 4 red.
According to our system of comparison, NKTX is a better buy in the long-term than GYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 6 TA indicator(s) are bullish while NKTX’s TA Score has 6 bullish TA indicator(s).

  • GYRE’s TA Score: 6 bullish, 4 bearish.
  • NKTX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both GYRE and NKTX are a good buy in the short-term.

Price Growth

GYRE (@Biotechnology) experienced а -1.90% price change this week, while NKTX (@Biotechnology) price change was -0.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

GYRE is expected to report earnings on Nov 18, 2026.

NKTX is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
GYRE
Daily Signal:
Gain/Loss:
NKTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBPTX62.660.39
+0.63%
Neuberger Large Cap Value Tr
IJSAX11.78N/A
N/A
VY® JPMorgan Small Cap Core Equity A
PGRTX17.58N/A
N/A
Principal SmallCap Growth I Instl
RMQHX648.19N/A
N/A
Rydex Monthly Rbl NASDAQ-100® 2x Strt H
IEQAX20.56-0.01
-0.05%
ICON Equity Income Investor

NKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with EDIT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
+3.56%
EDIT - NKTX
52%
Loosely correlated
+1.89%
RCKT - NKTX
50%
Loosely correlated
-3.74%
PRME - NKTX
48%
Loosely correlated
-6.57%
RXRX - NKTX
48%
Loosely correlated
+1.27%
VIR - NKTX
47%
Loosely correlated
+0.38%
More